Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

NCT06230354 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

EGPA - Eosinophilic Granulomatosis With Polyangiitis

Interventions

DRUG: Tezepelumab
DRUG: Placebo

Sponsor

Imperial College London

Collaborators

[object Object]